

Dabrafenib BREAK-3

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Improved QoL

Serious and disabling adverse effects




Other adjustments



Dabrafenib BREAK-3

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers
Therapeutic Indication: Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
Experimental Arm: Dabrafenib
Control Arm: Dacarbazine

